

Echocardiogr. 2024;37:809-19.

22. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults. *Eur Heart J Cardiovasc Imaging*. 2015;16:233-70.

23. Sugimoto T, Robinet S, Dulgheru R, Bernard A, Ilardi F, Contu L, et al. Echocardiographic reference ranges for normal left atrial function parameters: results from the EACVI NORRE study. *Eur Heart J Cardiovasc Imaging*. 2018;19(6):630-8.

24. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. *Cardiovasc Res*. 2000;45(4):813-25.

25. Makrygiannis SS, Margariti A, Rizikou D, Lampakis M, Vangelis S, Ampartzidou OS, et al. Incidence and predictors of new-onset atrial fibrillation in noncardiac intensive care unit patients. *J Crit Care*. 2014;29(4):697 e1-5.

26. Lancini D, Sun J, Mylonas G, Boots R, Atherton J, Prasad S, et al. Predictors of New Onset Atrial Fibrillation Burden in the Critically Ill. *Cardiology*. 2024;149(2):165-73.

27. Balik M, Maly M, Brozek T, Rulisek J, Sachl R, Porizka M, et al. Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial. *Intensive Care Med*. 2023;49(11):1283-92.

28. Waldauf P, Porizka M, Horejsek J, Otahal M, Svobodova E, Jurisinova I, et al. The outcomes of patients with septic shock treated with propafenone compared to amiodarone for supraventricular arrhythmias are related to end-systolic left atrial volume. *Eur Heart J Acute Cardiovasc Care*. 2024;13:414-22.

29. Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, et al; J-Land 3S Study Group. Efficacy and safety of landiolol, an ultra-short-acting β_1 -selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. *Lancet Respir Med*. 2020 Sep;8(9):863-872.

30. Whitehouse T, Delaney AP, McAuley DF, Gordon AC, Bion J, Young D, et al. Landiolol and Organ Failure in Patients With Septic Shock (STRESS-L): Randomized Clinical Trial. *JAMA*. 2023;330(17):1641-52.

31. Rehberg S, Frank S, Černý V, Cihlák R, Borgstedt R, Biancofiore G, et al. Landiolol for

heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). *Intensive Care Med*. 2024;50:1622-34.

32. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med*. 2021;47:1181-247.

33. Arrigo M, Jaeger N, Seifert B, Spahn DR, Bettex D, Rudiger A. Disappointing Success of Electrical Cardioversion for New-Onset Atrial Fibrillation in Cardiosurgical ICU Patients. *Crit Care Med*. 2015;43(11):2354-9.

34. Balik M, Vignon P, Chew MS, Tavazzi G, Mayo P, Doufle G, et al. Echocardiography guided management of atrial fibrillation. *Intensive Care Med*. 2025;51:1855-66.

35. Alexandru MG, Niewald P, Krüger S, Borgstedt R, Whitehouse T, Singer M, et al. Mortality in septic patients treated with short-acting betablockers: a comprehensive meta-analysis of randomized controlled trials. *Crit Care*. 2024;28(1):392.

36. Levy B, Slama M, Lakbar I, Maizel J, Kato H, Leone M, et al. Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review. *J Clin Med*. 2024;13:2951.

37. Walkey AJ, Quinn EK, Winter MR, McManus DD, Benjamin EJ. Practice Patterns and Outcomes Associated With Use of Anticoagulation Among Patients With Atrial Fibrillation During Sepsis. *JAMA Cardiol*. 2016;1(6):682-690.

38. Induruwa I, Hennebry E, Hennebry J, Thakur M, Warburton EA, Khadjooi K. Sepsis-driven atrial fibrillation and ischaemic stroke. Is there enough evidence to recommend anticoagulation? *Eur J Intern Med*. 2022;98:32-6.

39. Ayirala S, Kumar S, O'Sullivan DM, Silverman DI. Echocardiographic predictors of left atrial appendage thrombus formation. *J Am Soc Echocardiogr*. 2011;24(5):499-505.

40. Nakagami H, Yamamoto K, Ikeda U, Mitsuhashi T, Goto T, Shimada K. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. *Am Heart J*. 1998;136(3):528-32.

41. Van Laer SL, Verreyen S, Winkler KM, Miljoen H, Sarkozy A, Heuten H, et al. Effect of Mitral Regurgitation on Thrombotic Risk in Patients With Nonrheumatic Atrial Fibrillation: A New CHA(2)DS(2)-VASc Score Risk Modifier? *Am J Cardiol*. 2021;145:69-76.